Aditxt Plans Public Spinout of Ignite Proteomics

Aditxt, Inc. has announced a definitive business combination agreement that will enable its wholly owned subsidiary, Ignite Proteomics, to become an independent publicly traded company in a transaction valuing the precision oncology firm at approximately $150 million.

The proposed deal marks a significant milestone for both companies and reflects Aditxt’s strategy of identifying, developing, and unlocking value from innovative healthcare technologies. Upon completion of the transaction, Ignite Proteomics is expected to separate from Aditxt and operate as an independent company through a newly established public holding company anticipated to be named Ignite Proteomics, Inc.

Under the terms of the agreement, the acquisition corporation involved in the transaction and Ignite Proteomics will become wholly owned subsidiaries of the new public holding company. The company plans to seek a listing of its common stock and public warrants on the New York Stock Exchange, subject to regulatory approvals, listing requirements, and customary closing conditions.

The transaction is expected to create value for Aditxt shareholders while allowing the parent company to continue operating independently as a Nasdaq-listed company. Aditxt stated that the separation will provide greater visibility into the value of Ignite, which it currently owns in its entirety, while enabling both organizations to pursue distinct growth strategies.

Jeff Busch, Interim Chief Executive Officer of Aditxt and Chief Executive Officer of Ignite Proteomics, described the agreement as a transformational step for both companies.

According to Busch, the business combination recognizes Ignite’s position as a differentiated precision oncology company and provides a pathway to accelerate its growth. He noted that while Ignite gains access to public capital markets and greater operational focus, Aditxt will continue advancing its broader healthcare innovation portfolio as a standalone public company.

Ignite Proteomics is focused on advancing functional proteomics technologies designed to improve treatment decision-making in oncology. Unlike conventional genomic approaches that infer biological activity from DNA mutations, Ignite’s platform directly measures protein and phosphoprotein signaling within tumor tissue. The company believes this approach can provide clinicians with a more accurate understanding of tumor behavior and help identify the most effective therapies for individual patients.

The company’s initial commercial efforts are concentrated in breast cancer, although its long-term strategy includes expanding into additional cancer types and treatment settings. Management believes its technology could become increasingly relevant as oncology continues shifting toward highly targeted therapies, including antibody-drug conjugates, immunotherapies, and precision medicines.

Following the completion of the transaction, Ignite intends to focus on expanding clinical adoption of its platform, scaling commercial operations, generating additional clinical evidence, and pursuing collaborations with academic institutions, cancer centers, healthcare providers, payors, and pharmaceutical companies.

The company expects net proceeds from the business combination, including funds remaining in the acquisition corporation’s trust account after shareholder redemptions and any additional financing secured as part of the transaction, to support commercialization initiatives, research activities, working capital requirements, and general corporate operations.

The proposed spinout reflects a broader trend across the biotechnology industry, where specialized healthcare companies are seeking independent public listings to gain direct access to capital markets and accelerate commercialization efforts. For Ignite Proteomics, the transaction is expected to provide the financial resources and market visibility needed to advance its functional proteomics platform and strengthen its position in the rapidly evolving precision oncology sector.

If completed as planned, the transaction would establish Ignite as a standalone public company focused on transforming cancer treatment decisions through advanced protein-based diagnostics, while allowing Aditxt to continue pursuing opportunities across its broader healthcare innovation portfolio.